IL33 and atopic eczema: A phase 2a study of a single intravenous 300 mg dose of etokimab, a humanized IgG1/kappa anti–IL-33 monoclonal, in 12 adult patients with moderate-to-severe atopic dermatitis, has recently been published [167].